Northern Trust Corp Acquires 25,732 Shares of Genmab A/S Sponsored ADR $GMAB

Key Points

• Northern Trust Corp has increased its stake in Genmab A/S by 4.3%, holding 625,113 shares worth approximately $12.24 million after purchasing an additional 25,732 shares.
• Multiple institutional investors, including Two Sigma Advisers LP and Russell Investments Group Ltd., have significantly increased their positions in Genmab A/S, reflecting growing confidence in the company.
• Wall Street analysts have mixed ratings for Genmab A/S, with a consensus rating of "Moderate Buy" and an average price target of $37.60, indicating potential for future growth.

Northern Trust Corp raised its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 4.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 625,113 shares of the company's stock after buying an additional 25,732 shares during the quarter. Northern Trust Corp owned about 0.10% of Genmab A/S worth $12,240,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GMAB. Two Sigma Advisers LP grew its stake in shares of Genmab A/S by 168.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock worth $34,509,000 after buying an additional 1,038,400 shares during the last quarter. Two Sigma Investments LP raised its holdings in Genmab A/S by 122.2% in the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock worth $35,612,000 after purchasing an additional 938,455 shares during the period. Russell Investments Group Ltd. raised its holdings in Genmab A/S by 111.5% in the 1st quarter. Russell Investments Group Ltd. now owns 1,080,129 shares of the company's stock worth $21,149,000 after purchasing an additional 569,345 shares during the period. Voloridge Investment Management LLC raised its holdings in Genmab A/S by 102.4% during the fourth quarter. Voloridge Investment Management LLC now owns 1,110,191 shares of the company's stock valued at $23,170,000 after acquiring an additional 561,767 shares during the period. Finally, DDD Partners LLC grew its position in shares of Genmab A/S by 165.9% during the first quarter. DDD Partners LLC now owns 601,050 shares of the company's stock valued at $11,769,000 after purchasing an additional 374,976 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Wall Street Zen upgraded Genmab A/S from a "hold" rating to a "buy" rating in a research report on Monday, July 28th. HC Wainwright lifted their price target on Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a research report on Friday, August 15th. Zacks Research lowered Genmab A/S from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Finally, Truist Financial lifted their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $37.60.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB traded down $0.10 during trading hours on Wednesday, hitting $27.73. 1,219,253 shares of the company's stock traded hands, compared to its average volume of 1,334,638. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $28.03. The business has a fifty day moving average price of $23.24 and a 200-day moving average price of $21.57. The firm has a market capitalization of $17.79 billion, a P/E ratio of 13.93, a price-to-earnings-growth ratio of 1.62 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.